Despite the pathophysiological bases of this mechanism are clear and support the use of the PD-1/PD-L1 blockade, data in clinical practice are contrasting and to date the relationship between PD-L1 expression and host-tumor immunity in HCC is not well defined. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.